Review Article
Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?
Table 2
Summary of hazard ratio of <65 versus >=65 with esophageal cancer in clinical trials.
| | Authors/reference #/year | N <65
| N >=65
| Age mean (range) | Age Difference
HR (95% CI):
| PFS (> 60 versus ≤ 60 years) | Univariable HR Age (> 60 versus ≤ 60 years) |
| Robb W.B. et al.
/[4]/2015 | - | - | 57·8 (36·9–76·4) | | locoregional recurrence
1·49 (0·81, 2·76) | metastatic recurrence 0·88 (0·49, 1·60) |
| Zhao Y, et al.
/[5]/2015 | 174 | 172 | 59 (23-90) | (<65 vs >=65)
HR (95% CI):<60: 0.85(0.69-1.05)
60-69: 0.92(0.67-1.25)
>70:0.93(0.62-1.39) | - | - |
| | Dutton S.J. et al. /[2]/2014 | - | - | 64.8(58.0-70.7) | - | - | - |
| Oppedijk V. et al.
/[7]/2014 | - | - | 60(36-79) | - | - | - |
| | Swisher S.G. et al. [8]/2010 | - | - | 58(23-77) | 1.0 (0.9–1.1) | - | - |
| | Crehange G. et al./[9]/2007 | - | - | 59 | 1.01 (0.99 to 1.03)
Local Relapse-Free Survival
1.01 (1.00 to 1.02)
Overall Survival | - | - |
| | Burmeister B.H. et al./[10]/2005 | - | - | 62(28-83) | - | PFS
HR:1.43(1.06-1.99)
P:0.02 | Overall survival 1·53 (1·14–2·06) |
|
|
